...
首页> 外文期刊>Nature Communications >Preclinical safety study of a combined therapeutic bone wound dressing for osteoarticular regeneration
【24h】

Preclinical safety study of a combined therapeutic bone wound dressing for osteoarticular regeneration

机译:联合治疗性骨创面愈合的骨关节再生的临床前安全性研究

获取原文
           

摘要

The extended life expectancy and the raise of accidental trauma call for an increase of osteoarticular surgical procedures. Arthroplasty, the main clinical option to treat osteoarticular lesions, has limitations and drawbacks. In this manuscript, we test the preclinical safety of the innovative implant ARTiCAR for the treatment of osteoarticular lesions. Thanks to the combination of two advanced therapy medicinal products, a polymeric nanofibrous bone wound dressing and bone marrow-derived mesenchymal stem cells, the ARTiCAR promotes both subchondral bone and cartilage regeneration. In this work, the ARTiCAR shows 1) the feasibility in treating osteochondral defects in a large animal model, 2) the possibility to monitor non-invasively the healing process and 3) the overall safety in two animal models under GLP preclinical standards. Our data indicate the preclinical safety of ARTiCAR according to the international regulatory guidelines; the ARTiCAR could therefore undergo phase I clinical trial.
机译:预期寿命的延长和意外创伤的增加要求增加骨关节外科手术程序。关节置换术是治疗骨关节病变的主要临床选择,具有局限性和缺点。在本文中,我们测试了创新植入物ARTiCAR在治疗骨关节病变中的临床前安全性。得益于两种先进疗法的药用产品,聚合的纳米纤维骨创面敷料和源自骨髓的间充质干细胞的结合,ARTiCAR促进了软骨下骨和软骨的再生。在这项工作中,ARTiCAR显示了1)在大型动物模型中治疗骨软骨缺损的可行性,2)无创监测愈合过程的可能性以及3)在GLP临床前标准下在两种动物模型中的总体安全性。我们的数据表明,根据国际法规指南,ARTiCAR的临床前安全性;因此,ARTiCAR可以进行I期临床试验。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号